{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:26:17Z","timestamp":1761582377379,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201700020C"],"award-info":[{"award-number":["HHSO100201700020C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ebiom.2024.105334","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:04:10Z","timestamp":1726160650000},"page":"105334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-584X","authenticated-orcid":false,"given":"Bei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelynn","family":"Golubov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaozhi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarissa","family":"Lett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kaczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2170-3162","authenticated-orcid":false,"given":"Lewis Oscar","family":"Felix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia K.","family":"Mylona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-3366","authenticated-orcid":false,"given":"Matthew F.","family":"Wipperman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Chio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C.","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea T.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"Somersan-Karakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-211X","authenticated-orcid":false,"given":"Bret J.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Petro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Sleeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Kalliolias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Skokos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2024.105334_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2024.105334_bib2","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) a randomised, controlled, open-label, platform trial","author":"Group","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2024.105334_bib3","article-title":"REGEN-COV antibody combination and outcomes in outpatients with covid-19","author":"Weinreich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2024.105334_bib5","first-page":"1","article-title":"Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination","author":"Schaefer-Babajew","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2024.105334_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3041","article-title":"The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination","volume":"14","author":"Benschop","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790469","article-title":"Endogenous antibody responses to SARS-CoV-2 in patients with mild or moderate COVID-19 who received bamlanivimab alone or bamlanivimab and etesevimab together","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2022.09.016","article-title":"Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2","volume":"124","author":"Rotundo","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105334_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163471","article-title":"Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses","volume":"7","author":"Ramirez","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2024.105334_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.08.002","article-title":"Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19","volume":"182","author":"Silvin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2024.105334_bib11","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2024.105334_bib12","first-page":"1","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2024.105334_bib14","first-page":"533","article-title":"A\u00a0single-cell atlas of the peripheral immune response in patients with severe COVID-19","volume":"20","author":"Wilk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2024.105334_bib16","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunologic features in severe and moderate Coronavirus Disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ebiom.2024.105334_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91270-8","article-title":"Persistent symptoms and lab abnormalities in patients who recovered from COVID-19","volume":"11","author":"Varghese","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2024.105334_bib18","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2024.105334_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac320","article-title":"Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19","author":"Somersan-Karakaya","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105334_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01699-22","article-title":"Casirivimab and imdevimab treatment reduces viral load and improves clinical outcomes in seropositive hospitalized COVID-19 patients with nonneutralizing or borderline neutralizing antibodies","volume":"13","author":"Hooper","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.ebiom.2024.105334_bib21","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2024.105334_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2024.105334_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100287","article-title":"Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions","author":"Filbin","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64827","article-title":"Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death","volume":"10","author":"Gisby","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ebiom.2024.105334_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib26","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1038\/s41467-022-32551-2","article-title":"Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19","volume":"13","author":"Chew","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2024.105334_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/infdis\/jiad446","article-title":"Effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19","volume":"229","author":"Jensen","year":"2023","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2024.105334_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 transmission and pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/onc.2016.221","article-title":"KRT19 directly interacts with \u03b2-catenin\/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties","volume":"36","author":"Saha","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ebiom.2024.105334_bib30","first-page":"1636","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Valle","year":"2020","journal-title":"Nat\u00a0Med"},{"key":"10.1016\/j.ebiom.2024.105334_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The Cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ebiom.2024.105334_bib32","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41423-021-00728-2","article-title":"Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection","volume":"18","author":"P\u00e9rez-G\u00f3mez","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib33","first-page":"186","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat\u00a0Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg5021","article-title":"Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19","volume":"6","author":"Notarbartolo","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ebiom.2024.105334_bib35","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMoa2209502","article-title":"Convalescent plasma for covid-19\u2013induced ARDS in mechanically ventilated patients","volume":"389","author":"Misset","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424003700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424003700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:47:36Z","timestamp":1729108056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424003700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"alternative-id":["S2352396424003700"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105334","relation":{},"ISSN":["2352-3964"],"issn-type":[{"type":"print","value":"2352-3964"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105334"}}